News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexo AB Reports Regulatory Approval of Edluar® in Europe


6/18/2012 10:30:25 AM

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (“Orexo”)(STO:ORX) is pleased to report that Edluar® has received regulatory approval in Europe, according to information supplied by Meda AB (“Meda”), Orexo’s global commercial partner for the product. Edluar®, a sublingual formulation of zolpidem, is indicated for treatment of insomnia characterized by difficulties with sleep initiation, and was developed by Orexo using the Company’s proprietary sublingual formulation technologies

Read at BioSpace.com


comments powered by Disqus
Orexo AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES